Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYC140 in Advanced Solid Tumors and Lymphoma
2024-516290-67-00Phase 2Completed
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of plogosertib in Nonhematologic neoplasms, lymphoma and cutaneous T-cell lymphoma (CTCL), sponsored by Cyclacel Pharmaceuticals, Inc. Primary endpoints: Incidence rate of dose-limiting toxicities (DLTs) in first cycle (Phase 1 dose escalation) and Overall response rate (ORR) (Phase 2 proof of concept). Started Aug 2024; status: completed.
02
Drugs
plogosertib
03
Conditions
Nonhematologic neoplasmslymphomacutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on 2024-516290-67-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516290-67-00.